Deferoxamine Mesylate
Who holds supplier records for Deferoxamine Mesylate? 2 organisations hold a current record for Deferoxamine Mesylate: an active US FDA Type II Drug Master File or a CEP. A further 3 organisations have only historical (inactive) DMF filings. 2 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: Germany (1) and Netherlands (1).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Deferoxamine Mesylate: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/deferoxamine-mesylate
Reading the evidence
- 2 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 1 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (2)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Deferoxamine Mesylate. Country is the organisation's recorded country, not necessarily the manufacturing site.
- EXCELLA GMBH AND CO KGGermanyCEP Company GMP cert on recordActive DMF 18459, 25421 · latest filing Mar 2012
- TAPI NL BVNetherlandsCEPActive DMF 12241 · latest filing Dec 1996
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (2)
Certificates of Suitability on the EDQM register for Deferoxamine Mesylate, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| TAPI NL B.V. Amsterdam | NL | CEP 2000-160 - Rev 05 Deferoxamine mesilate, Produced by fermentation | Jul 2026 | — |
| EXCELLA GMBH & CO. KG Feucht | DE | CEP 2009-401 - Rev 06 Deferoxamine mesilate, Produced by a synthetic process | Mar 2025 | Inspected Apr 2026 Germany |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Historical records (3)
Organisations whose Type II DMFs for Deferoxamine Mesylate are no longer active. These show a past filing, not current supply.
Show all 3 historical records
- United States · Inactive DMF 20253 · filed Feb 2007
- France · Inactive DMF 16653 · filed Jun 2003
- United States · Inactive DMF 10041 · filed Jan 1993
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Deferoxamine Mesylate is a chelating agent used to remove excess iron from the body in conditions of chronic iron overload, such as thalassemia or secondary hemochromatosis. It forms a stable complex with iron, which is then excreted from the body, thus reducing iron concentration.
Chemical identity
- IUPAC name
- N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide;methanesulfonic acid
- Canonical SMILES
- CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O.CS(=O)(=O)O
- InChIKey
- IDDIJAWJANBQLJ-UHFFFAOYSA-N
- Synonyms
- Desferal API, ba-33112, deferoxamine mesilate, deferoxamine methanesulfonate, deferoxamini mesilas, desferal, desferrioxamine mesilate, desferrioxamine mesylate, nsc-756718
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Iron Chelator
- Mechanism of action
- Iron Chelating Activity
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Deferoxamine Mesylate?
2 organisations hold an active US FDA Type II Drug Master File or a CEP for Deferoxamine Mesylate: EXCELLA GMBH AND CO KG (Germany) and TAPI NL BV (Netherlands). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Deferoxamine Mesylate Drug Master Files are active?
EXCELLA GMBH AND CO KG (DMF 18459, 25421) and TAPI NL BV (DMF 12241). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Deferoxamine Mesylate records mean?
3 organisations have only inactive Type II DMFs for Deferoxamine Mesylate. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does Deferoxamine Mesylate have a European Certificate of Suitability?
Yes. 2 organisations hold a valid CEP for Deferoxamine Mesylate on the EDQM register, including TAPI NL B.V. Amsterdam (NL) and EXCELLA GMBH & CO. KG Feucht (DE). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
How do I qualify a Deferoxamine Mesylate supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Deferoxamine Mesylate?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.